How to Help Patients with Olfactory Reference Syndrome Delusion of Body Odor Causes Shame, Social Isolation

Total Page:16

File Type:pdf, Size:1020Kb

How to Help Patients with Olfactory Reference Syndrome Delusion of Body Odor Causes Shame, Social Isolation CP_0307_Phillips.FinalREV 2/16/07 12:06 PM Page 49 How to help patients with olfactory reference syndrome Delusion of body odor causes shame, social isolation Katharine A. Phillips, MD Professor of psychiatry and human behavior Brown Medical School ® Dowden Health Media Providence, RI David J. Castle, MDCopyright St. Vincent's Hospital For personal use only The University of Melbourne Australia s. A, a 21-year-old M teacher, recalled al- ways having been “sensi- tive,” but when she started her first job at age 19 she began to believe that she emitted an offensive odor. She experienced thoughts that she passed offensive fla- tus, her breath had a fecal odor, and people noticed © 2007 Smithsonian Institution/Corbis and were offended. Gradually Ms. A became more convinced of Patients with olfactory reference syndrome (ORS) these distressing beliefs and began to think that falsely believe they emit an offensive body odor. she permeated fecal odor through her skin. She Prominent referential thinking—believing that also became sure that colleagues were talking other people perceive the odor—also is common. about her and that they complained about her To introduce you to ORS, we discuss its clinical “disgusting” smell. diagnosis and treatment based on our review of VOL. 6, NO. 3 / MARCH 2007 49 For mass reproduction, content licensing and permissions contact Dowden Health Media. CP_0307_Phillips.FinalREV 2/16/07 12:06 PM Page 50 Olfactory reference syndrome Box 1 ings. She tried to keep meeting room doors Patient troubled by ‘a very bad odor open and believed that colleagues held their ... which came from his own person’ hands to their noses to “protect” themselves from her odor. Olfactory reference syndrome (ORS) has been described around the world for more than a ORS symptoms are most often reported as begin- century. In 1891, Potts described a delusional ning when patients are in their mid 20s, 50-year-old man who “had been troubled for the although some reports suggest onset during past three months with smelling a very bad odor, puberty or adolescence.4 In clinical series, the which he likened to that of a ‘back-house,’ and ratio of men to women is approximately 2:1. which came from his own person. [He believed] this smell was so very strong that other men Preoccupation. Individuals with ORS are preoccu- objected to working with him….” pied with the belief that they emit an unpleasant or 1,2,5-9 Despite its long history, the syndrome’s offensive body odor (Box 1), most commonly: prevalence is not well-established. ORS probably • flatulence, fecal, or anal odors is underdiagnosed and more common than • general body odor generally recognized: • halitosis • In a tertiary psychiatry unit in London, 0.5% • genital odors.1-3 of 2,000 patients who were not systematically Other perceived odors include sweat, armpit screened for ORS spontaneously reported ORS odor, sperm, urine, and malodorous hands and symptoms. feet.1-3 Occasionally, the imagined odor resembles • In a self-report survey of 2,481 students in nonbodily smells, such as ammonia or detergent. Japan, 2.1% had been concerned with emitting The odor is perceived to emanate from corre- a strange bodily odor during the past year. sponding body areas, such as the anus, skin, • In a study in a dental clinic in Japan, the mouth, rectum, genitalia, feet, nose, or axillae. majority of patients with a primary complaint Although most reports suggest that patients of halitosis actually had “imaginary halitosis” (another term for ORS). focus on one odor, some describe being concerned about several smells simultaneously or different Source: References 1,2,5–9 odors over time.10,11 Referential thinking. As the syndrome’s name several hundred cases, including the largest implies, many ORS patients have delusions of ref- reported series of patients with ORS.1-4 erence, falsely believing that other people per- ceive the odor.3 They misinterpret the behavior of CLINICAL FEATURES OF ORS others, assuming it is a reaction to how the Ms. A quit her job and felt confident enough to patient smells (Box 2, page 52).2,3 work again only when she performed a 2-hour They may misperceive comments (such as, daily cleansing routine, doused herself in per- “It’s stuffy in here”), receiving perfume or soap as fume, and placed an incontinence pad in her a gift, or behaviors such as people sniffing, touch- underwear. Despite these precautions, she still ing or rubbing their nose, clearing their throat, thought her colleagues avoided her. opening a window to get fresh air, putting a She always averted her mouth when speak- newspaper in front of their face, or looking or ing, held her hand in front of her mouth, and sat moving toward or away from the patient.1,3,5,7 far from others and close to the door in meet- Because they are ashamed, embarrassed, and continued on page 52 50 VOL. 6, NO. 3 / MARCH 2007 CP_0307_Phillips.FinalREV 2/16/07 12:06 PM Page 52 Olfactory reference syndrome continued from page 50 Box 2 Patients may change jobs repeatedly or avoid 3 Delusion, hallucination, or both? school or work because of shame and embarrass- ment, a belief that other people talk about the DSM-IV-TR classifies olfactory reference syndrome supposed odor, or the patient’s excessive preoccu- (ORS) as a delusional disorder, somatic type pations and time-consuming repetitive and safe- (the modern equivalent of monosymptomatic ty behaviors.5,13,14 hypochondriacal psychosis). ORS also is The distress and impaired functioning may mentioned in the text on social anxiety disorder. lead to psychiatric hospitalization, depression, ORS may not be diagnosed if: suicidal ideation, suicide attempts, and complet- • criterion A for schizophrenia has ever been met ed suicide.7,10,12,15 Pryse-Phillips studied 36 pa- • or if symptoms are due to the direct physiologic tients with ORS and reported: effects of a substance or a general medical • nearly one-half (43%) experienced “suicidal condition, such as a brain tumor or temporal lobe epilepsy. ideas or action” • 2 (5.6%) committed suicide.3 Many patients report being able to smell the Illness course. imagined odor, suggesting that they experience Most authors suggest that ORS is an olfactory hallucination. Pryse-Phillips described usually chronic, persisting for years if not the olfactory hallucinations of her 36 ORS case decades, with possible worsening over time if patients as “a real and immediate perception... patients do not receive appropriate treatment.11,15 often perceived in the absence of other odors.” In a 2-year follow-up study,3 ORS symptoms per- ORS generally is regarded as delusional, with sisted relatively unchanged in 10 of 11 patients. possible secondary illusional misinterpretations Some authors have questioned whether ORS and referential thinking. ORS beliefs usually can transform into schizophrenia, but others have appear to be of delusional intensity, although found little evidence for this.3,6 some patients may have some—although limited —insight (that is, overvalued ideation). Psychiatric comorbidity. Depression is mentioned most often in the literature.12,13 In Pryse-Phillips’ Source: References 2 and 3 36 ORS patients (who did not have a “primary” depressive disorder), depression symptoms tend- ed to be severe.3 The depression generally is con- concerned about offending others with their odor,13 sidered secondary to ORS, although Pryse- many patients engage in repetitive and “safety” Phillips evaluated 50 additional patients with behaviors intended to check, eliminate, or camou- ORS symptoms whom she considered to have a flage the supposed odor (Box 3, page 55).1,3,7,12,14 “primary” depressive disorder.3 Other psychiatric Functional impairment. Individuals with ORS comorbidities include bipolar disorder, personali- often avoid other people or believe that others ty disorder, schizophrenia, hypochondriasis, alco- avoid them.12 They are typically embarrassed and hol and/or drug abuse, obsessive-compulsive dis- worried that others will be offended by the smell. order (OCD), and body dysmorphic disorder.3,7,15 They may: In a study of 200 individuals with body dysmor- • avoid activities such as dating phic disorder, 8 had comorbid ORS.16 • break off engagements • refuse to travel DIAGNOSING ORS • move to another town Clinical clues to ORS (Table 1, page 60) probably • become housebound.3,7,10,12 are not present in all patients and some are not continued on page 55 52 VOL. 6, NO. 3 / MARCH 2007 CP_0307_Phillips.Final 2/14/07 1:40 PM Page 55 continued from page 52 specific to ORS. They appear to be common fea- Box 3 tures of the illness, however, and may alert you to ‘Safety’ and avoidance behaviors its presence. Our clinical impression is that many seen in olfactory reference syndrome patients with ORS are secretive about their symp- toms because they are ashamed of them. Thus, you Excessive showering or washing are among need to be alert to clues and specifically inquire the repetitive, ritualistic or “safety” behaviors about ORS symptoms to detect its presence. many patients with ORS engage in to check, Criteria. DSM-IV-TR and ICD-10 lack specific eliminate, or camouflage supposed odor. Frequent diagnostic criteria for ORS, instead applying cri- clothes changing or laundering also is common. teria for delusional disorder. One problem with Camouflaging attempts may include excessive use of deodorant, soap, cologne, powder, mints, this approach is that delusional disorder criteria mouthwash, or toothpaste; wearing layers specify that any co-occurring mood symptoms of clothing; or smoking. must be brief relative to the duration of the delu- Many patients frequently check for the odor sional periods. This requirement may not be valid or its source (such as trying to smell their own when applied to ORS.
Recommended publications
  • AMANTADIP\Dle: on Nemolebtic-II[WDUCED CATALEPSY UV the RAT
    J. Fac. Plmnz. Istanbul lstanbul Ecz. Fak. Mec. 29, 1 (1993) 29, 1 (1993) THE EFFECT OF CYPROHEPT~~AWEb AMANTADIP\dlE: ON NEmOLEBTIC-II[WDUCED CATALEPSY UV THE RAT SUMMARY Catalepsy is not a unitary phenomenon. With respect to biochemical mechanisms and neurotransmitter sytems, the origin of this behavioural response varies according to different substances which cause catalepsy. For example, the catdeptogenic effect of ne- uroleptics has been related to the blockage of striatal doparnine receptors. Neurophysio- logical and biochemical data have shown that a mechanism caused by gama-aminobuty- ric acid and serotonin have been effective in the proper functioning of the dopaminergic nigrosbriatal tract. We have studied the effects of cyproheptadine, a serotonin antagonist, and of amantadin which is used in the treatment of Parkinson syndrome on the catalepsy indu- ced by trifluoperazine, a phenothiazin compound, and pimozid, a drug used as a neuro- leptic. It was observed that when rats were pretreated with cyproheptadine as well as amantadiie, the catalepsy induced by the above neuroleptic drugs was attenuated. The results of our study show that substances which have an effect on the seroto- nergic and dopaminergic systems also play a role on cases of catalepsy induced by the neuroleptic drugs mentioned above. (*) Faculty of Pharmacy, Depament of Pharmacology, University of Istanbul, 31152, Istanbul, Turkey Katalepsi bir tek nedene bagh OWortaya qllian bit durum degildir. Biyokimya- sal ve norotransmitter sistemler agsmdan bu davran~glnsebebi, katalepsi olughYan qe- gitli maddeler iqin fad&&. Omegin noroleptiklerin kataleptojenik etkisi striatal dopa- min reseptorlerinin blokaj~nabajjlanmqtx. Niirofizyolojik ve biyokimyasal veriler do- pamine jik nigro-striatal sistemin duzenli $&$masmda gma-aminobutirik asid ve sero- tonin'e bagh olan bir mekanizmmn etkili oldugunu gostermigtir.
    [Show full text]
  • Delusional Parasitosis Mimicking Cutaneous Infestation in Elderly Patients
    LESSONS FROM PRACTICE LESSONS FROM PRACTICE Delusional parasitosis mimicking cutaneous infestation in elderly patients Clinical records Patient 1 Patient 3 An 88-year-old man gave a 12-month history of seeing insects attacking An 81-year-old woman was referred with a persistent belief that his legs and crawling along the floor of his house. He described these she had scabies and lice infestation of her eyes, nose, arms and insects as 4 cm long, black and white bugs with beaks, which pecked anus. This resulted in her persistently washing her clothes and at hisThe legs, Medical causing Journal wounds. of He Australia often felt ISSN:a sharp 0025-729X stinging sensation 18 herself and reporting the retirement village where she lived to the heraldingAugust their 2003 presence. 179 4 209-210 He also had burning pain in both legs below Health Department. She had received anti-scabies treatment the knees. He had had his house fumigated twice in the previous year empirically. ©The Medical Journal of Australia 2003 www.mja.com.au andLessons put various from chemicals practice across his doorways and bed to ward off the She had a long history of severe depression after the death of her bugs. He described no other hallucinations or delusions. husband, for which she took doxepin. She had paranoid ideation He was not using any regular medications and had never been a about her neighbours and saw things crawling down the walls, consumer of alcohol. He lived alone and managed all activities of and had moved residences several times to avoid these problems.
    [Show full text]
  • Schizophrenia Care Guide
    August 2015 CCHCS/DHCS Care Guide: Schizophrenia SUMMARY DECISION SUPPORT PATIENT EDUCATION/SELF MANAGEMENT GOALS ALERTS Minimize frequency and severity of psychotic episodes Suicidal ideation or gestures Encourage medication adherence Abnormal movements Manage medication side effects Delusions Monitor as clinically appropriate Neuroleptic Malignant Syndrome Danger to self or others DIAGNOSTIC CRITERIA/EVALUATION (PER DSM V) 1. Rule out delirium or other medical illnesses mimicking schizophrenia (see page 5), medications or drugs of abuse causing psychosis (see page 6), other mental illness causes of psychosis, e.g., Bipolar Mania or Depression, Major Depression, PTSD, borderline personality disorder (see page 4). Ideas in patients (even odd ideas) that we disagree with can be learned and are therefore not necessarily signs of schizophrenia. Schizophrenia is a world-wide phenomenon that can occur in cultures with widely differing ideas. 2. Diagnosis is made based on the following: (Criteria A and B must be met) A. Two of the following symptoms/signs must be present over much of at least one month (unless treated), with a significant impact on social or occupational functioning, over at least a 6-month period of time: Delusions, Hallucinations, Disorganized Speech, Negative symptoms (social withdrawal, poverty of thought, etc.), severely disorganized or catatonic behavior. B. At least one of the symptoms/signs should be Delusions, Hallucinations, or Disorganized Speech. TREATMENT OPTIONS MEDICATIONS Informed consent for psychotropic
    [Show full text]
  • Psychedelics in Psychiatry: Neuroplastic, Immunomodulatory, and Neurotransmitter Mechanismss
    Supplemental Material can be found at: /content/suppl/2020/12/18/73.1.202.DC1.html 1521-0081/73/1/202–277$35.00 https://doi.org/10.1124/pharmrev.120.000056 PHARMACOLOGICAL REVIEWS Pharmacol Rev 73:202–277, January 2021 Copyright © 2020 by The Author(s) This is an open access article distributed under the CC BY-NC Attribution 4.0 International license. ASSOCIATE EDITOR: MICHAEL NADER Psychedelics in Psychiatry: Neuroplastic, Immunomodulatory, and Neurotransmitter Mechanismss Antonio Inserra, Danilo De Gregorio, and Gabriella Gobbi Neurobiological Psychiatry Unit, Department of Psychiatry, McGill University, Montreal, Quebec, Canada Abstract ...................................................................................205 Significance Statement. ..................................................................205 I. Introduction . ..............................................................................205 A. Review Outline ........................................................................205 B. Psychiatric Disorders and the Need for Novel Pharmacotherapies .......................206 C. Psychedelic Compounds as Novel Therapeutics in Psychiatry: Overview and Comparison with Current Available Treatments . .....................................206 D. Classical or Serotonergic Psychedelics versus Nonclassical Psychedelics: Definition ......208 Downloaded from E. Dissociative Anesthetics................................................................209 F. Empathogens-Entactogens . ............................................................209
    [Show full text]
  • Drug Repurposing Opportunities in Pancreatic Ductal Adenocarcinoma
    pharmaceuticals Review Drug Repurposing Opportunities in Pancreatic Ductal Adenocarcinoma Rita Rebelo 1,2,† ,Bárbara Polónia 1,2,†,Lúcio Lara Santos 3,4, M. Helena Vasconcelos 1,2,5,* and Cristina P. R. Xavier 1,2,5,* 1 Cancer Drug Resistance Group, IPATIMUP—Institute of Molecular Pathology and Immunology, University of Porto, 4200-135 Porto, Portugal; [email protected] (R.R.); [email protected] (B.P.) 2 i3S—Instituto de Investigação e Inovação em Saúde, Universidade do Porto, 4200-135 Porto, Portugal 3 Experimental Pathology and Therapeutics Group, IPO—Instituto Português de Oncologia, 4200-072 Porto, Portugal; [email protected] 4 ICBAS—Biomedical Sciences Institute Abel Salazar, Universidade do Porto, 4050-313 Porto, Portugal 5 Department of Biological Sciences, FFUP—Faculty of Pharmacy of the University of Porto, 4200-135 Porto, Portugal * Correspondence: [email protected] (M.H.V.); [email protected] (C.P.R.X.) † These authors equally contributed to this work. Abstract: Pancreatic ductal adenocarcinoma (PDAC) is considered one of the deadliest tumors worldwide. The diagnosis is often possible only in the latter stages of the disease, with patients already presenting an advanced or metastatic tumor. It is also one of the cancers with poorest prognosis, presenting a five-year survival rate of around 5%. Treatment of PDAC is still a major challenge, with cytotoxic chemotherapy remaining the basis of systemic therapy. However, no major advances have been made recently, and therapeutic options are limited and highly toxic. Thus, novel therapeutic options are urgently needed. Drug repurposing is a strategy for the development of novel treatments using approved or investigational drugs outside the scope of the original clinical indication.
    [Show full text]
  • CENTRAL NERVOUS SYSTEM DEPRESSANTS Opioid Pain Relievers Anxiolytics (Also Belong to Psychiatric Medication Category) • Codeine (In 222® Tablets, Tylenol® No
    CENTRAL NERVOUS SYSTEM DEPRESSANTS Opioid Pain Relievers Anxiolytics (also belong to psychiatric medication category) • codeine (in 222® Tablets, Tylenol® No. 1/2/3/4, Fiorinal® C, Benzodiazepines Codeine Contin, etc.) • heroin • alprazolam (Xanax®) • hydrocodone (Hycodan®, etc.) • chlordiazepoxide (Librium®) • hydromorphone (Dilaudid®) • clonazepam (Rivotril®) • methadone • diazepam (Valium®) • morphine (MS Contin®, M-Eslon®, Kadian®, Statex®, etc.) • flurazepam (Dalmane®) • oxycodone (in Oxycocet®, Percocet®, Percodan®, OxyContin®, etc.) • lorazepam (Ativan®) • pentazocine (Talwin®) • nitrazepam (Mogadon®) • oxazepam ( Serax®) Alcohol • temazepam (Restoril®) Inhalants Barbiturates • gases (e.g. nitrous oxide, “laughing gas”, chloroform, halothane, • butalbital (in Fiorinal®) ether) • secobarbital (Seconal®) • volatile solvents (benzene, toluene, xylene, acetone, naptha and hexane) Buspirone (Buspar®) • nitrites (amyl nitrite, butyl nitrite and cyclohexyl nitrite – also known as “poppers”) Non-Benzodiazepine Hypnotics (also belong to psychiatric medication category) • chloral hydrate • zopiclone (Imovane®) Other • GHB (gamma-hydroxybutyrate) • Rohypnol (flunitrazepam) CENTRAL NERVOUS SYSTEM STIMULANTS Amphetamines Caffeine • dextroamphetamine (Dexadrine®) Methelynedioxyamphetamine (MDA) • methamphetamine (“Crystal meth”) (also has hallucinogenic actions) • methylphenidate (Biphentin®, Concerta®, Ritalin®) • mixed amphetamine salts (Adderall XR®) 3,4-Methelynedioxymethamphetamine (MDMA, Ecstasy) (also has hallucinogenic actions) Cocaine/Crack
    [Show full text]
  • Medications to Be Avoided Or Used with Caution in Parkinson's Disease
    Medications To Be Avoided Or Used With Caution in Parkinson’s Disease This medication list is not intended to be complete and additional brand names may be found for each medication. Every patient is different and you may need to take one of these medications despite caution against it. Please discuss your particular situation with your physician and do not stop any medication that you are currently taking without first seeking advice from your physician. Most medications should be tapered off and not stopped suddenly. Although you may not be taking these medications at home, one of these medications may be introduced while hospitalized. If a hospitalization is planned, please have your neurologist contact your treating physician in the hospital to advise which medications should be avoided. Medications to be avoided or used with caution in combination with Selegiline HCL (Eldepryl®, Deprenyl®, Zelapar®), Rasagiline (Azilect®) and Safinamide (Xadago®) Medication Type Medication Name Brand Name Narcotics/Analgesics Meperidine Demerol® Tramadol Ultram® Methadone Dolophine® Propoxyphene Darvon® Antidepressants St. John’s Wort Several Brands Muscle Relaxants Cyclobenzaprine Flexeril® Cough Suppressants Dextromethorphan Robitussin® products, other brands — found as an ingredient in various cough and cold medications Decongestants/Stimulants Pseudoephedrine Sudafed® products, other Phenylephrine brands — found as an ingredient Ephedrine in various cold and allergy medications Other medications Linezolid (antibiotic) Zyvox® that inhibit Monoamine oxidase Phenelzine Nardil® Tranylcypromine Parnate® Isocarboxazid Marplan® Note: Additional medications are cautioned against in people taking Monoamine oxidase inhibitors (MAOI), including other opioids (beyond what is mentioned in the chart above), most classes of antidepressants and other stimulants (beyond what is mentioned in the chart above).
    [Show full text]
  • FDA Indications2
    Schizophrenia Bipolar, acute mania Bipolar, acute mixed Bipolar, maintenance MDD GAD Social Anxiety D/O Panic D/O PTSD PsychiatricOCD Indications PMDD Bulimia nervosa Insomnia EPS ADHD TCA=tricyclic antidepressant MAO-I=monoamine oxidase inhibitor MDD=major depressive d/o GAD=generalized anxiety d/o OCD=obsessive compulsive d/o PMDD=pre-menstrual dysphoric d/o EPS=extrapyramidal symptoms ADHD=attention deficit hy *for treatment-resistant schizo **includes ***includes amantadine, benztro ªBHCS non-formular conventional APs XXXXXX p X XXXXXXaripiprazole X henelzine, tran ☼ X X XXXX Updated December 13, 2005 XXclozapin XXe* All conventional antipsychotics (except pimozide) below Oral Medications Used in Adult Psychiatry ♦ ☼ olanzapine Lorazepam, oxazepam, alprazolam See y medication quetiapine y lc risperidone p yp ♣ hrenia onl romine, isocarboxazid All tricyclic antidepressants are indicated for ziprasidone p ine, bi carbamazepine p y divalproex Na iriden, di ; also indicated for reduction in risk of recurrent suicidal behaviors in schizo Chlorpromazine gabapentinª lamotrigine p henh lithium Temazepam, triazolam, flurazepam y dramine, trihex oxcarbazepineª Diazepam topiramateª is also indicated for treatment of TCAs , and HaloperidolPimozide citalopram and yp chlordiazepoxide Diazepam XXX XXXXXXXXescitalopram henid ♣ below chlordiazepoxide are indicated for See fluoxetine XX X yl is only Clonazepam fluvoxamine is also indicated for XXX X is indicated for relief of paroxetine Depression XXXX indicated for XXX sertraline X XX bupropion are indicated for XX is indicated for Schizophrenia/management of manifestations of Psychotic D/Os duloxetineª are indicated for , and , except MAO-Is** A Tourette's D/O. cute mania associated with Bipolar D/O. estazolam mirtazapine Tourette's D/O. trazodone clomipramine p venlafaxine Acute anixety "Anxiety D/O or short-term relief of symptoms of anxiety." hrenia or schizoaffective d/o Panic D/O.
    [Show full text]
  • NEUROPSYCHOCUTANEOUS DISORDERS Maren Gaul, DO Tri County Dermatology Disclosures
    NEUROPSYCHOCUTANEOUS DISORDERS Maren Gaul, DO Tri County Dermatology Disclosures No relevant financial relationships or conflicts of interest to disclose. Psychodermatology Cutaneous disorders psychiatric in nature, with absence of organic dermatologic causes. Delusions of Parasitosis Firm fixation that he/she has parasitic infection. Close contact may share delusion. Female: Male 2:1, middle to older age. “ziplock sign” patient will often bring in epithelial debris in ziplock as proof. Associated with schizophrenia, depression, anxiety, drug/alcohol abuse, dementia and obsessive states. May experience sensations of biting, crawling or stinging. Practitioner needs to distinguish delusion from substance-induced formication. Skin Findings range from none to excoriations, lichenification, prurigo nodularis and/or frank ulcerations. Delusions of Parasitosis: Management Establish rapport with the patient and to address the chief complaint seriously, making sure to do a thorough dermatologic examination. Diagnosis of exclusion, rule out infestation, underlying dermatologic condition. Consider biopsy and laboratory workup to rule out organic etiology. Present antipsychotic medication in pragmatic manner. Delusions of parasitosis: Management Psychiatry is preferable but is often rejected by the patient. Past: Pimozide 1-4mg treatment of choice. SE extrapyramidal & prolonged QT interval Newer atypical antipsychotic agents like risperidone and olanzapine are now consider first- line agents. With appropriate pharmacologic intervention, some literature suggestion 50% of patients will remit. Psychogenic (neurotic) excoriations Unconscious compulsive habit of picking at themselves, so persistent that excoriations develop. Typical on contralateral side of hand dominance. Could be ritualistic or random areas. Most common in middle-aged women. Different degrees of healing and scarring. Most commonly associated with depression, obsessive-compulsive disorder and anxiety.
    [Show full text]
  • Pharmacology 49, 301 - 306 (1976) Psycho- ' Pharmacology © by Springer-Verlag 1976
    J Psychopharmacology 49, 301 - 306 (1976) Psycho- ' pharmacology © by Springer-Verlag 1976 Comparison of the Action of Lysergic Acid Diethylamide and Apomorphine on the Copulatory Response in the Female Rat MONA ELIASSON* and BENGT J. MEYERSON Department of Medical Pharmacology, University of Uppsala, Box 573, S-75123 Uppsala, Sweden Abstract. The effects of lysergic acid diethylamide relationship between the hormone treatment and the (LSD) and apomorphine were compared using female lordosis response, measured as in the present investiga- copulatory behavior (lordosis response), in ovari- tion (Meyerson, 1964a, 1967). ectomized estrogen + progesterone-treated rats. Both Accumulating data indicate monoaminergic in- serotonin and dopamine are implicated in the inhibi- volvement in the control of the lordosis response. tion of this behavior. Each compound inhibited Meyerson (1964a, b), testing a large number of com- lordosis behavior dose dependently and with a similar pounds with different effects on monoaminergic trans- time-course. Pimozide (0.1; 0.5 mg/kg) blocked the mitter mechanisms, found the most pronounced in- apomorphine (0.2 mg/kg)-induced decrease of lor- hibitory effects after treatments that increase sero- dosis response, while only a certain abbreviation of tonergic (5-HT) receptor activity, which pointed the LSD (0.10 mg/kg) inhibition was achieved by to the existence of serotonergic neurons mediating pimozide (0.5 mg/kg). Chlorpromazine (0.5 mg/kg) in inhibition of the female copulatory behavior. Later a dose without effects
    [Show full text]
  • Drug-Induced Parkinsonism
    InformationInformation Sheet Sheet Drug-induced Parkinsonism Terms highlighted in bold italic are defined in increases with age, hypertension, diabetes, the glossary at the end of this information sheet. atrial fibrillation, smoking and high cholesterol), because of an increased risk of stroke and What is drug-induced parkinsonism? other cerebrovascular problems. It is unclear About 7% of people with parkinsonism whether there is an increased risk of stroke with have developed their symptoms following quetiapine and clozapine. See the Parkinson’s treatment with particular medications. This UK information sheet Hallucinations and form of parkinsonism is called ‘drug-induced Parkinson’s. parkinsonism’. While these drugs are used primarily as People with idiopathic Parkinson’s disease antipsychotic agents, it is important to note and other causes of parkinsonism may also that they can be used for other non-psychiatric develop worsening symptoms if treated with uses, such as control of nausea and vomiting. such medication inadvertently. For people with Parkinson’s, other anti-sickness drugs such as domperidone (Motilium) or What drugs cause drug-induced ondansetron (Zofran) would be preferable. parkinsonism? Any drug that blocks the action of dopamine As well as neuroleptics, some other drugs (referred to as a dopamine antagonist) is likely can cause drug-induced parkinsonism. to cause parkinsonism. Drugs used to treat These include some older drugs used to treat schizophrenia and other psychotic disorders high blood pressure such as methyldopa such as behaviour disturbances in people (Aldomet); medications for dizziness and with dementia (known as neuroleptic drugs) nausea such as prochlorperazine (Stemetil); are possibly the major cause of drug-induced and metoclopromide (Maxolon), which is parkinsonism worldwide.
    [Show full text]
  • 65 © Elsevier/North-Holland Biomedical Press MONOAMINE REPLACEMENT AFTER RESERPINE: CATECHOLAMINERGIC AGONISTS RESTORE MOTOR AC
    Brain Research, 202 (1980) 65-77 65 © Elsevier/North-Holland Biomedical Press MONOAMINE REPLACEMENT AFTER RESERPINE: CATECHOLAMINERGIC AGONISTS RESTORE MOTOR ACTIVITY BUT PHENYLETHYLAMINE RESTORES ATROPINE-RESISTANT NEOCORTICAL LOW VOLTAGE FAST ACTIVITY C. I-I. VANDERWOLF,T. E. ROBINSON and B. A. PAPPAS Department of Psychology, University of Western Ontario, London, Ontario, N6A 5C2 (Canada), ( T.E.R.) University of Michigan, Ann Arbor, Mich. 48109 (U.S.A.) and ( B.A.P.) Carleton University, Ottawa, KI S 5B6 (Canada) (Accepted May 29th, 1980) Key words: reserpine -- monoamines -- motor activity -- atropine -- neocortical activity SUMMARY A large dose of reserpine abolishes an atropine-resistant form of neocortical low voltage fast activity (LVFA) which normally accompanies certain patterns of motor activity in rats. An attempt was made to reverse this effect by replacement of specific monoamines or by injection of suitable agonists in rats pretreated with reserpine (10 mg/kg). The following compounds, alone or in various combinations, failed to restore atropine-resistant LVFA in reserpinized rats even though spontane- ous motor activity was restored in many cases: L-DOPA (150--300 mg/kg) after pretreatment with an inhibitor of peripheral L-aromatic amino acid decarboxylase; 5- hydroxytryptophan (100-200 mg/kg); D-amphetamine (1-2 mg/kg); apomorphine (0.25-2.5 mg/kg); lysergic acid diethylamide (100-300/~g/kg); and clonidine (0.5-1.0 mg/kg). In contrast fl-phenylethylamine was quite effective in restoring atropine- resistant LVFA and its effects were not diminished by pretreatment with a-methyl-p- tyrosine (400 mg/kg), chlorpromazine (15 mg/kg) or trifluoperazine (5-10 mg/kg).
    [Show full text]